1stOncology™: Cancer Intelligence Service – Page 13785 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Grant of Share Options under Share Option Scheme

On May 22, 2019 Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) reported that on May 21, 2019, it granted share options under the Share Option Scheme conditionally adopted by Chi-Med at its Annual General Meeting in 2015 (the "2015 HCML Share Option Scheme") (Press release, Hutchison China MediTech, MAY 22, 2019, https://www.chi-med.com/grant-of-share-options-under-share-option-scheme/ [SID1234556762]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Chi-Med granted 18,000 share options under its 2015 HCML Share Option Scheme to certain employees to subscribe for Ordinary Shares subject to the acceptance of the grantees. Details of such share options granted prescribed are as follows:

Date of grant: May 21, 2019

Exercise price of share options granted: GBP42.20 per Ordinary Share

Number of share options granted: 18,000 (each share option shall entitle the holder thereof to subscribe for one Ordinary Share)

Closing market price of Ordinary Shares on the date of grant: GBP42.20 per Ordinary Share

Validity period of the share options: From May 21, 2019 to May 20, 2029

Probiodrug to attend International Conferences in June 2019

On May 22, 2019 Probiodrug AG ("Probiodrug", Euronext: PBD), reported that the company is scheduled to attend the following conferences (Press release, Vivoryon Therapeutics, MAY 22, 2019, View Source [SID1234537420]):

(1) 2019 BIO International Convention

June 3-6, 2019, Pennsylvania Convention Center, Philadelphia, PA, USA

Dr. Ulrich Dauer, CEO, and Dr. Michael Schaeffer, CBO, to attend and host meetings

(2) Biotech CEO Summit Europe

June 17-19, 2019, Enniskerry, Ireland

Dr. Ulrich Dauer, CEO, to attend

For more information, please contact:

Probiodrug
Dr. Ulrich Dauer, CEO
Email: [email protected]

MC Services AG
Anne Hennecke, Susanne Kutter
Tel: +49 (0) 211 529 252 27
Email: [email protected]

Compugen to Present at the Jefferies 2019 Healthcare Conference

On May 22, 2019 Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, reported that Anat Cohen-Dayag, PhD, President and CEO, will present a corporate overview and update at the Jefferies 2019 Healthcare Conference in New York, on Tuesday, June 4, 2019, at 4:30 PM ET (Press release, Compugen, MAY 22, 2019, View Source [SID1234536537]).

To access live webcast of the presentation, please visit Compugen’s website. An archived version of the presentation will be available after the presentation ends at the same location.

IDEAYA Announces Pricing of Initial Public Offering

On May 22, 2019 IDEAYA Biosciences, Inc. (Nasdaq:IDYA) reported the pricing of its initial public offering of 5,000,000 shares of common stock at a public offering price of $10.00 per share, before underwriting discounts and commissions (Press release, Ideaya Biosciences, MAY 22, 2019, View Source [SID1234536536]). All of the shares of common stock are being offered by IDEAYA. In addition, IDEAYA has granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of common stock at the initial public offering price, less the underwriting discounts and commissions. IDEAYA’s common stock is expected to begin trading on the Nasdaq Global Market on May 23, 2019, under the ticker symbol "IDYA". The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by IDEAYA, are expected to be $50.0 million, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on May 28, 2019, subject to the satisfaction of customary closing conditions.

J.P. Morgan, Citigroup and Jefferies acted as joint book-running managers for the offering.

A registration statement relating to the shares being sold in this offering was declared effective by the Securities and Exchange Commission on May 22, 2019. The offering is being made only by means of a prospectus, copies of which may be obtained, when available, from: J.P. Morgan, by mail at J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at 866-803-9204, or by email at [email protected]; Citigroup, by mail at Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at 1-800-831-9146; or Jefferies, by mail at Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by telephone at 877-547-6340 or 877-821-7388, or by email at [email protected].

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

Medicure Q1 2019 Results and Conference Call Dates

On May 22, 2019 Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a pharmaceutical company, reported that it will release financial results for the quarter ended March 31, 2019 on Monday, May 27, 2019 (Press release, Medicure, MAY 22, 2019, View Source [SID1234536535]). The first quarter financial statements will be made available on the Company’s website at www.medicure.com. Medicure will hold a conference call and webcast regarding the results on Tuesday, May 28, 2019 at 7:30 AM Central Time (8:30 AM Eastern Time).

Conference Call Info:

Topic: Medicure’s Q1 2019 Results

Call date: Tuesday, May 28, 2019

Time: 7:30 AM Central Time (8:30 AM Eastern Time)

Canada toll-free: 1 (888) 465-5079 Canada toll: 1 (416) 216-4169

United States toll-free: 1 (888) 545-0687

Passcode: 6562291#

Webcast: This conference call will be webcast live over the internet and can be accessed from the Medicure investor relations page at the following link: View Source

You may request international country-specific access information by e-mailing the Company in advance. Management will accept and answer questions related to the financial results and operations during the question-and-answer period at the end of the conference call. A recording of the call will be available following the event at the Company’s website.